Vitamin D2 vs D3: Why Cholecalciferol Is the Clear Winner

The Vitamin D Confusion Nobody Talks About

Walk into any pharmacy and you'll find shelves stacked with vitamin D supplements. Look closely at the labels, though, and you'll notice something worth paying attention to: some say "D2" (ergocalciferol) and others say "D3" (cholecalciferol). The numbers look similar, the doses are often identical, and the price difference can be negligible — so most people grab whichever is cheapest or what their doctor prescribed.

That choice, it turns out, is far from trivial.

Vitamin D deficiency affects an estimated 1 billion people worldwide, according to a global review published in Reviews in Endocrine and Metabolic Disorders (Palacios & Gonzalez, 2014; PMID: 24065765). In the United States alone, the National Health and Nutrition Examination Survey (NHANES) data has consistently shown that 40% or more of American adults have insufficient 25-hydroxyvitamin D [25(OH)D] levels (below 50 nmol/L). Despite the scale of this deficiency, much of the clinical conversation has focused on how much vitamin D to take rather than which form is actually superior.

The evidence, however, is now robust enough that the question of vitamin D2 vs D3 deserves a direct answer — and that answer points clearly toward cholecalciferol.

---

Cholecalciferol vs Ergocalciferol: What's the Structural Difference?

Both D2 and D3 are fat-soluble secosteroids that the body converts into the active hormone 1,25-dihydroxyvitamin D (calcitriol). Their paths to that endpoint, however, differ in meaningful ways.

Vitamin D2 (ergocalciferol) is plant-derived and produced commercially by irradiating ergosterol, a compound found in yeast and fungi. It has a slightly different side chain — an extra methyl group and a double bond — compared to D3.

Vitamin D3 (cholecalciferol) is the form synthesized in human skin when UVB radiation hits 7-dehydrocholesterol. It is also found naturally in fatty fish, egg yolks, and liver. Its molecular structure is identical to what the body produces endogenously, which is a critical advantage when it comes to receptor affinity, transport protein binding, and metabolic half-life.

The structural difference between D2 and D3 isn't cosmetic. It affects how each form binds to vitamin D-binding protein (DBP), how quickly it is metabolized by the liver, and — most clinically important — how effectively it raises and sustains circulating 25(OH)D.

---

Vitamin D3 Absorption: The Metabolic Case for Cholecalciferol

The liver converts both D2 and D3 into 25(OH)D via the enzyme CYP2R1 (and to a lesser extent CYP27A1). But the kinetics differ substantially. Vitamin D3 binds more tightly to vitamin D-binding protein than D2 does, which means it remains in circulation longer and is less rapidly cleared by the kidneys and liver.

A landmark randomized controlled trial by Tripkovic et al. (2017), published in The American Journal of Clinical Nutrition, is among the most rigorous direct comparisons available. In this 12-week RCT involving 335 South Asian and white European women, daily supplementation with 15 mcg (600 IU) of vitamin D3 raised serum 25(OH)D by significantly more than an equivalent dose of D2. The D3 group achieved 25(OH)D concentrations roughly 75% higher than the D2 group at study end (Tripkovic et al., Am J Clin Nutr, 2017; PMID: 28646829).

This wasn't a one-off finding. A 2012 meta-analysis by Tripkovic et al. in the same journal, analyzing 10 RCTs, concluded that vitamin D3 is more effective than D2 at raising serum 25(OH)D concentrations when taken daily, with the effect becoming even more pronounced over longer supplementation periods (Tripkovic et al., Am J Clin Nutr, 2012; PMID: 22552031).

Why does the duration matter? Because D3's superior binding to DBP effectively acts like a slow-release depot. When you stop supplementing, D3-driven 25(OH)D levels decline more gradually than those raised by D2, providing a buffer against the deficiency that so commonly re-emerges when people forget doses or change routines.

For anyone interested in the clinical evidence for vitamin D and immune function, this difference in absorption kinetics isn't academic — it directly determines whether your supplementation strategy actually moves you into the optimal 25(OH)D range (generally considered 75–125 nmol/L by many functional medicine practitioners).

---

Vitamin D Bioavailability: Why Form Matters More Than Dose

Vitamin D bioavailability is influenced by three intersecting factors: the molecular form (D2 vs D3), the delivery format (capsule, softgel, liquid), and co-ingested nutrients — particularly dietary fat.

The fat co-ingestion effect is well established. A 2015 RCT by Dawson-Hughes et al., published in the Journal of the Academy of Nutrition and Dietetics, found that taking vitamin D with a fat-containing meal increased absorption by approximately 32% compared to a fat-free meal (Dawson-Hughes et al., 2015; PMID: 25441954). This finding applies to both D2 and D3, but matters more for D3 because maximizing D3 absorption amplifies an already superior molecule.

Delivery format also shapes bioavailability. Oil-based softgels and liquid drops tend to outperform dry tablet formulations in individuals with malabsorption conditions (e.g., Crohn's disease, short bowel syndrome, or pancreatic insufficiency). For the general population, the difference is smaller but still measurable.

Genetic polymorphisms in the GC gene (which encodes DBP) and in the CYP2R1 and CYP27B1 enzymes can significantly alter how any form of vitamin D is processed. This is one reason some individuals remain deficient despite taking seemingly adequate doses — a reality that underscores why personalized vitamin D3 and K2 dosing based on blood work is more effective than population-wide flat dosing recommendations.

For comparison, platforms like Viome focus primarily on gut microbiome data when building recommendations, while Thorne offers practitioner-grade D3/K2 supplements without personalized dosing calibration. Neither approach integrates blood 25(OH)D levels, genetic context, and wearable data into a single formula the way Ones does.

---

Vitamin D Supplement Form: Does Prescription D2 Need Rethinking?

Here's a clinical irony worth noting: in the United States, prescription-strength vitamin D (typically 50,000 IU capsules) is almost universally dispensed as D2 (ergocalciferol). This has historical and regulatory roots — D2 received FDA approval for prescription use decades before D3 was recognized as the superior form — but it means millions of Americans being treated for deficiency are receiving the less bioavailable option.

A 2014 review in the Journal of Clinical Endocrinology & Metabolism directly addressed this disconnect, arguing that the evidence now strongly supports cholecalciferol (D3) as the preferred supplement form for correcting deficiency, and called for reconsideration of current prescribing conventions (Heaney & Holick, JCEM, 2011; PMID: 21646368). Several systematic reviews since have reinforced this position.

The practical implication: if you're taking a doctor-prescribed 50,000 IU D2 weekly, you may not be raising your 25(OH)D as effectively as you would with a well-dosed daily D3 protocol — particularly because D3's longer half-life makes it more amenable to daily lower-dose supplementation, which keeps levels steadier than weekly high-dose spikes.

For those exploring the broader landscape of fat-soluble vitamins, understanding the vitamin D3 and K2 synergy is particularly important: D3 increases calcium absorption, and vitamin K2 (MK-7) ensures that calcium is deposited into bones rather than soft tissue — a pairing that no thoughtful D3 supplementation protocol should ignore.

---

The K2 Partnership: Why D3 Alone Isn't the Full Picture

Discussing vitamin D3 without mentioning K2 (menaquinone-7, or MK-7) is like discussing calcium without mentioning bone matrix. The two nutrients work in concert: D3 upregulates the production of osteocalcin and matrix Gla protein (MGP), both of which require K2 for carboxylation to become functionally active.

Without adequate K2, the elevated calcium absorption driven by D3 can paradoxically increase vascular calcification risk. A 2015 study in Thrombosis and Haemostasis found that MK-7 supplementation (180 mcg/day for three years) in postmenopausal women significantly improved arterial stiffness markers and activated MGP levels compared to placebo (Knapen et al., Thrombosis and Haemostasis, 2015; PMID: 25694037).

This biochemical partnership is why optimal magnesium glycinate dosage also enters the picture: magnesium is a cofactor for vitamin D's conversion to its active form (25(OH)D and then 1,25(OH)₂D). Research published in The American Journal of Clinical Nutrition (Deng et al., 2013; PMID: 23719551) found that magnesium intake significantly predicted circulating 25(OH)D levels — meaning that even excellent D3 supplementation can underperform in the presence of magnesium insufficiency.

---

What This Means for Your Formula: How Ones Addresses the D2 vs D3 Question

Ones builds personalized supplement formulas by analyzing your actual blood 25(OH)D levels, health history, and goals — not by assigning everyone the same RDA. Here's how the platform handles the evidence around vitamin D:

1. Vitamin D3 + K2 (MK-7): Ones uses cholecalciferol (D3) paired with vitamin K2 as MK-7, dosed specifically to move your 25(OH)D into the functional target range. Rather than defaulting to a flat 1,000 IU or 2,000 IU, the formula calibrates dose based on your lab-reported baseline — a critical distinction given that the required dose to move from deficient to optimal varies widely by individual (typically 2,000–5,000 IU for deficient adults, per NIH ODS guidance).

2. Magnesium Glycinate: Ones includes magnesium glycinate as part of its Magnesium Complex, recognizing the cofactor role magnesium plays in vitamin D metabolism. The glycinate form is prioritized for its superior absorption and reduced laxative effect compared to magnesium oxide.

3. Omega-3 (EPA/DHA): Because vitamin D3 is fat-soluble and absorption is enhanced by dietary fat, Ones pairs D3 with omega-3 fatty acids where appropriate — a practical delivery synergy supported by the fat co-ingestion bioavailability data. You can explore the evidence in more depth via this omega-3 EPA DHA ratio guide.

The result is a D3 protocol that doesn't just add cholecalciferol to your capsule plan but accounts for the metabolic environment that determines whether D3 actually works.

---

Key Takeaways

• D3 (cholecalciferol) is superior to D2 (ergocalciferol) for raising and sustaining serum 25(OH)D, with head-to-head RCTs showing D3 producing up to 75% higher blood levels than equivalent D2 doses (Tripkovic et al., 2017; PMID: 28646829).
• Bioavailability of both forms increases with dietary fat, but maximizing D3 absorption amplifies the advantage of an already more potent molecule — take your D3 supplement with a fat-containing meal.
• Prescription D2 (50,000 IU ergocalciferol) is widely used for deficiency correction but is less effective than D3 at the same dose; consult your healthcare provider about switching protocols.
• K2 (MK-7) is a necessary partner for D3 — it ensures calcium is directed to bones rather than arteries, and MK-7 at 180 mcg has been shown to improve arterial stiffness markers over three years (Knapen et al., 2015; PMID: 25694037).
• Magnesium is a required cofactor for vitamin D activation; deficiency in magnesium can blunt the effect of even well-dosed D3 supplementation.
• Personalized dosing based on actual 25(OH)D blood levels is the most evidence-aligned approach — population-level flat dosing frequently undershoots or overshoots individual needs.